Compare ABCL & GSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABCL | GSBD |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2020 | 2013 |
| Metric | ABCL | GSBD |
|---|---|---|
| Price | $3.05 | $9.08 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 5 | 1 |
| Target Price | $7.75 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 3.8M | 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 14.10% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.82 |
| Revenue | ★ $28,833,000.00 | N/A |
| Revenue This Year | $26.18 | N/A |
| Revenue Next Year | $13.51 | N/A |
| P/E Ratio | ★ N/A | $11.07 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.89 | $8.92 |
| 52 Week High | $6.52 | $13.30 |
| Indicator | ABCL | GSBD |
|---|---|---|
| Relative Strength Index (RSI) | 40.69 | 36.87 |
| Support Level | $3.06 | $9.13 |
| Resistance Level | $3.24 | $9.55 |
| Average True Range (ATR) | 0.21 | 0.21 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 39.68 | 0.00 |
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests primarily in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.